3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
12
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Advanced Solid Tumors
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
ulixertinib
1
tislelizumab
1
talazoparib
1
serabelisib
1
sapanisertib
1
pembrolizumab
1
olaparib
1
mirdametinib
1
lenvatinib
1
erdafitinib
1
crenigacestat
1
atezolizumab
1
Ramucirumab
1
Paclitaxel
1
PM 01183
1
Injections
1
IFL protocol
1
Gemcitabine
1
Bosentan
1
BID protein, human
1
Appointments and Schedules
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumor
×
talazoparib
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts